## neither pregnant nor puerperal women: a population study

- 4 Fabiano Elisei Serra<sup>1</sup>, Rossana Pulcineli Vieira Francisco<sup>1\*</sup>, Patricia de Rossi<sup>2,3</sup>, Maria de Lourdes
- 5 Brizot<sup>1</sup>, Agatha Sacramento Rodrigues<sup>1,4\*</sup>
- 7 Disciplina de Obstetrícia, Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina da
- 8 Universidade de São Paulo, São Paulo, São Paulo, Brazil
- 9 <sup>2</sup> Curso de Medicina, Universidade de Santo Amaro (UNISA), São Paulo, São Paulo, Brazil
- 10 <sup>3</sup> Gerência de Medicina Perinatal e Ginecologia, Conjunto Hospitalar do Mandaqui, São Paulo, São
- 11 Paulo, Brazil

1

2

3

6

13

16

17

- <sup>4</sup>Departamento de Estatística, Universidade Federal do Espírito Santo, Vitória, Espírito Santo, Brazil
- 14 \*Corresponding author
- 15 E-mail: agatha.rodrigues@ufes.br (ASR)

### **Abstract**

- 18 Objective To compare hospitalized reproductive age women with COVID-19 who were pregnant,
- 19 puerperal, or neither one nor the other in terms of demographic and clinical characteristics and
- 20 disease progression using Brazilian epidemiological data.

# Introduction

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

COVID-19 is an infectious disease caused by the new coronavirus (SARS-CoV-2), and it has a clinical spectrum ranging from absence of symptoms to severe illness and death. Widespread contagion

and the ability of the virus to disseminate led the World Health Organization (WHO) to declare a pandemic state in March 2020 [1]. The high incidence has had a tremendous socioeconomic impact worldwide. One day prior to the submission of this article (June 28, 2021), globally, there were more than 180 million confirmed cases of COVID-19 and 3,923,238 deaths [2]. Since the beginning of the pandemic, the infection has been studied in the obstetric population to understand its consequences and to prevent adverse maternal-fetal outcomes. The initial publications describing COVID-19 cases in pregnant women in China, Europe, and North America did not report increased severity and deaths compared to the general population [3-9]. Subsequent studies, however, showed a higher likelihood of the need for admission to intensive care units (ICUs) and mechanical ventilation [10-14]. The first maternal deaths were reported in the United Kingdom, Iran, United States, Mexico, and France [15-19]. In Brazil, the high number of maternal deaths due to COVID-19 has been attributed to factors such as high birth rate, poor nutrition and health, difficult access to health services, and insufficient obstetric assistance [20,21]. Socioeconomic heterogeneity in Brazil is reflected in the quality of health services and in the availability of hospital and ICU beds, having a great impact on health indicators of both pregnant and puerperal women [22,23]. Understanding the disease and evaluating why the prognoses of pregnant and puerperal women have been worse in this pandemic is relevant. We did not find any studies comparing demographic and clinical characteristics and disease progression among pregnant women, puerperal women, and neither pregnant nor puerperal women hospitalized with COVID-19. Therefore, the authors of the present study aim to compare pregnant women, puerperal women, and neither pregnant nor puerperal women according to data related to the SARS-CoV-2 infection by using population statistics from SIVEP-Gripe (System of Information about Epidemiological Surveillance of Influenza) of the Health Ministry of Brazil.

66

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

## **Materials and methods**

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

A retrospective analysis of the statistics from SIVEP-Gripe, a Brazilian national database containing surveillance data on severe acute respiratory syndrome (SARS) was performed [24]. The notification of SARS is compulsory in cases of the flu syndrome (acute respiratory condition, characterized by at least two of the following signs and symptoms: fever [even if reported], chills, sore throat, headache, cough, coryza, and disorders of taste or smell), accompanied by dyspnea/respiratory distress, persistent chest pressure, oxygen saturation ( $SpO_2$ ) below 95% in room air, or cyanosis. The SIVEP-Gripe is notified of all cases of hospitalization both in public and in private hospitals, as well as of all deaths caused by SARS-CoV-2, irrespective of hospitalization. SIVEP-Gripe records include the following: demographic data (sex, age, skin color/ethnicity, obstetric status, schooling, city of residence); clinical data (signs and symptoms, risk factors/comorbidities); epidemiological data (previous flu vaccination, community-acquired infection, or nosocomial infection); laboratory and etiological diagnoses. There is also information about hospital admission, ICU admission, use of ventilatory support (invasive and noninvasive), and disease outcome (cure or death). Data search covered epidemiological weeks 1 to 53 (December 29, 2019 - January 02, 2021), with the last update on January 11, 2021; however, the first Brazilian records began in epidemiological week 8 (first day of symptoms of the first confirmed case was on February 17, 2020). Search included all data on female patients aged 10 to 49 years hospitalized with COVID-19, confirmed with a positive RT-PCR result for SARS-CoV-2. Cases were excluded if they were unhospitalized or unconfirmed with an RT-PCR for SARS-CoV-2, or if gender or pregnancy status were not recorded. The result was 40,640 women hospitalized with COVID-19 (RT-PCR+) and aged between 10 and 49 years, who were divided into two groups: pregnant women (n=3,372) and nonpregnant women

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

three study groups equivalent in relation to the confounding variables [25]. The first analysis, used

to compare the symptoms between groups, included age, ethnicity, chronic cardiovascular disease, asthma, diabetes, immunosuppression, and obesity. The second one, comparing the outcomes, included the same variables plus schooling, Federative Unit of Brazil, and respiratory symptoms.

The analyses were performed with the statistical R software (R Foundation for Statistical Computing Platform, version 4.0.3) [26] and PSM was carried out with the R Weightlt package [27].

### **Results**

A total of 40,640 reproductive age women hospitalized with a positive RT-PCR for SARS-CoV-2 result were identified. Of these, 3,372 were pregnant and 37,268 were not pregnant (Figure 1). Nonpregnant women comprised 794 puerperal women and 36,474 women who were neither pregnant nor puerperal. Groups differed significantly related to demographic data and comorbidities (Table 1). The group of neither pregnant nor puerperal women had the highest rate of comorbidities.

Figure 1: Study profile

Table 1. Demographic and clinical characteristics of reproductive age women with COVID-19 according to gestational status – Brazil, February 17, 2020 – January 02, 2021

Characteristics	Neither pregnant nor puerperal	Pregnant	Puerperal	р
Age (years)				
Mean ± SD	38.22 ± 8.25	29.64 ± 6.93	30.24 <b>±</b> 7.34	<0.0001
Age bracket (years)	n (%)	n (%)	n (%)	
<20	1,009 (2.8)	250 (7.4)	61 (7.7)	<0.0001
20-34	9,629 (26.4)	2,244 (66.5)	494 (62.2)	
>34	2,5836 (70.8)	878 (26.0)	239 (30.1)	
Total	36,474	3,372	794	
Skin color/Ethnicity	n (%)	n (%)	n (%)	
White	15,418 (54.0)	1,102 (40.5)	238 (37.2)	<0.0001
Black	1,679 (5.9)	192 (7.1)	46 (7.2)	

Yellow	359 (1.3)	33 (1.2)	4 (0.6)	
Brown	10,976 (38.5)	1,382 (50.8)	348 (54.4)	
Indigenous	97 (0.3)	13 (0.5)	4 (0.6)	
Total	28,529 (100)	2,722 (100)	640 (100)	
Schooling	n (%)	n (%)	n (%)	
No schooling	219 (1.4)	7 (0.5)	2 (0.6)	
Up to high school	3,661 (23.7)	360 (25.1)	81 (24.5)	<0.0001
High school	7,532 (48.7)	790 (55.1)	179 (54.2)	
College	4,058 (26.2)	277 (19.3)	68 (20.6)	
Total	15,470 (100)	1,434 (100)	330 (100)	
Risk factors and comorbidities	n (%)	n (%)	n (%)	
Chronic cardiovascular disease (n=14,976)	5780/13,330 (43.4)	214/1,141 (18.8)	77/505 (15.2)	<0.0001
Chronic hematologic disease (n=12,901)	356/11,340 (3.1)	16/1,081 (1.5)	11/480 (2.3)	0.006
Chronic hepatic disease (n=12,769)	189/11,226 (1.7)	8/1,066 (0.8)	4/477 (0.8)	0.0273
Asthma (n=13,426)	1883/11,821 (15.9)	139/1,119 (12.4)	33/486 (6.8)	<0.0001
Diabetes (n=14,575)	4825/12,934 (37.3)	241/1,151 (20.9)	61/490 (12.4)	< 0.0001
Chronic neurological disease (n=12,933)	568/11,377 (5.0)	25/1,078 (2.3)	5/478 (1.0)	<0.0001
Chronic lung disease (n=12,945)	579/11,390 (5.1)	23/1,075 (2.1)	5/480 (1.0)	<0.0001
Immunodepression (n=13,137)	1,289/11,578 (11.1)	40/1,078 (3.7)	18/481 (3.7)	<0.0001
Chronic renal disease (n=13,047)	1,080/11,495 (9.4)	24/1,073 (2.2)	12/479 (2.5)	<0.0001
Obesity (n=13,713)	3,741/12,135 (30.8)	143/1,097 (13.0)	53/481 (11.0)	< 0.0001
Metabolic syndrome	422/10,998 (3.8)	7/1,044 (0.7)	7/467 (1.5)	< 0.0001
(n=12,509)		·		
Number of comorbidities (n=11,958)	n (%)	n (%)	n (%)	< 0.0001
0	2,022/10,502 (19.3)	576/999 (57.7)	335/457 (73.3)	
1-2	7,681/10,502 (73.1)	408/999 (40.8)	106/457 (23.2)	
>2	799/10,502 (7.6)	15/999 (1.5)	16/457 (3.5)	

Table 2 shows the results of the comparison of COVID-19 symptoms before and after PSM in the three study groups. Both pregnant and puerperal women had a smaller chance of fever, cough, sore throat, dyspnea, respiratory discomfort, SpO<sub>2</sub><95%, diarrhea, vomiting, fatigue, SARI, and SARI without fever than neither pregnant nor puerperal women. Pregnant women had anosmia and ageusia more frequently than the others. Puerperal women had fewer chance of fever, coughing, vomiting, SARI, and SARI without fever than pregnant women; however, their oxygen saturation level was more frequently lower than 95% at hospital admission.

#### Brazil, February 17, 2020 - January 02, 2021

	Neither pregnant nor puerperal	Pregnant	Puerperal	Gı	roup comparise	on	Group comparison after PSM (age + ethnicity + cardiopathy + asthma + diabetes + immunosuppression + obesity)			
Signs, symptoms, and infection	n (%)	n (%)	n (%)	Pregnant vs. NPrNPu OR (95% CI)	Puerperal vs. NPrNPu OR (95% CI)	Puerperal vs. Pregnant OR (95% CI)	Pregnant vs. NPrNPu OR (95% CI)	Puerperal vs. NPrNPu OR (95% CI)	Puerperal vs. Pregnant OR (95% CI)	
Fe ver (n=36,371)	24,297/32,70	2,038/2,98	424/686	0.75 (0.69	0.56 (0.48	0.75 (0.63	0.78 (0.69	0.63 (0.53	0.81 (0.67	
	2 (74.3)	3 (68.3)	(61.8)	-0.81)	-0.65)	-0.89)	-0.88)	- 0.74)	- 0.93)	
Cough (n=37,101)	27,305/33,32	2,408/3,08	475/692	0.78 (0.72	0.48 (0.41	0.62 (0.51	1.19 (1.04	0.81 (0.67	0.68 (0.56	
	4 (81.9)	5 (78.1)	(68.6)	-0.86)	-0,57)	-0.74)	- 1.36)	- 0.97)	- 0.82)	
Sore throat	8,854/28,242	724/2,629	156/603	0.83 (0.76	0.76 (0.63	0.92 (0.75	0.88 (0.78	0.90 (0.74	1.02 (0.83	
(n=31,474)	(31.4)	(27.5)	(25.9)	-0,91)	-0.92)	- 1.12)	- 1.01)	- 1.10)	- 1.26)	
Dyspnea	25,134/32,66	1,761/2,94	381/668	0.45 (0.41	0.40 (0.34	0.89 (0.75	0.54 (0.48	0.54 (0.45	1.00 (0.84	
(n=36,272)	4 (76.9)	0 (59.9)	(57.0)	-0.48)	-0.47)	- 1.05)	-0.61)	- 0.64)	- 1.20)	
Respiratory discomfort (n=34,023)	20,158/30,60 0 (65.9)	1,374/2,77 1 (49.6)	341/652 (52.3)	0.51 (0.47 -0.55)	0.57 (0.49 -0.66)	1.11 (0.94 -1.32)	0.60 (0.54 -0.68)	0.73 (0.62 - 0.87)	1.21 (1.02 - 1.45)	
SpO <sub>2</sub> <95% (n=33,482) At least 1	17,109/30,13 7 (56.8)	860/2,708 (31.8)	291/637 (45.7) 490/703	0.35 (0.32 -0.39)	0.64 (0.55 -0.75) 0.29 (0.25	1.81 (1.52 -2.15)	0.40 (0.35 -0.45)	0.79 (0.67 - 0.94) 0.43 (0.36-	1.99 (1.65 - 2.39)	
respiratory symptom	30,208/34,00	2,177/3,02 1 (72.1)	(69.7)	0.32 (0.30 -0.35)	-0.34)	0.89 (0.75 - 1.07)	0.44 (0.38 - 0.51)	0.53)	0.98 (0.81 - 1.18)	
(n=37,726) Diarrhea (n=30,907)	6,387/27,758 (23.0)	335/2,574 (13.0)	65/575 (11.3)	0.50 (0.44 -0.56)	0.43 (0.33 -0.55)	0.85 (0.64 - 1.13)	0.61 (0.52 -0.71)	0.53 (0.41 - 0.70)	0.88 (0.66 - 1.18)	
Vomiting	4,148/27,206	342/2,566	45/570	0.86 (0.76	0.48 (0.35	0.56 (0.40	0.75 (0.63	0.47 (0.34	0.63 (0.45	
(n=30,342)	(15.2)	(13.3)	(7.9)	-0.96)	-0.64)	-0,77)	-0.89)	- 0.64)	- 0.87)	
Abdominal pain	13.47/14,360	117/1,175	20/240	1.07 (0.87	0.88 (0.54	0.83 (0.49	0.94 (0.69	0.75 (0.45	0.80 (0.48-	
(n=15,775)	(9.4)	(10.0)	(8.3)	- 1.30)	- 1.37)	- 1.33)	- 1.28)	- 1.24)	1.33)	
Fatigue	4,383/14,780	263/1,191	47/245	0.67 (0.58	0.56 (0.41	0.84 (0.59	0.95 (0.78	0.86 (0.61	0.90 (0.63	
(n=16,216) Anosmia	(29.7) 3,216/14,718	(22.1)	(19.2) 51/260	-0.77) 1.35 (1.18	-0.77) 0.87 (0.64	- 1.18) 0.65 (0.46	- 1.15) 1.79 (1.48	- 1.20) 1.26 (0.91	- 1.29) 0.70 (0.50	
(n=16,202)	(21.9)	(27.4)	(19.6)	- 1.54)	- 1.18)	-0.90)	- 2.17)	- 1.75)	- 0.99)	
Ageusia	3,121/14,634	297/1,212	45/257	1.20 (1.04	0.79 (0.56	0.66 (0.46	1.70 (1.41	1.17 (0.84	0.69 (0.48	
(n=16,103)	(21.3)	(24.5)	(17.5)	- 1.37)	- 1.08)	-0.92)	-2.04)	- 1.64)	0.99)	
SARI (n=34,118)	18,089/30,68	1,308/2,79	242/634	0.61 (0.57	0.43 (0.37	0.70 (0.59	0.78 (0.70	0.58 (0.49	0.74 (0.62	
	9 (58.9)	5 (46.8)	(38.2)	-0.66)	-0.51)	-0.84)	-0.88)	- 0.69)	- 0.89)	
SARI without	24,504/32,35	1,816/2,92	351/661	0.52 (0.48	0.36 (0.31	0.69 (0.58	0.75 (0.67	0.57 (0.48	0.75 (0.63	
fever (n=35,939)	3 (75.7)	5 (62.1)	(53.1)	-0.57)	-0.42)	-0.82)	-0.85)	- 0.67)	- 0.90)	
Hospital-acquired infection (n=30,722)	760/27,508 (2.8)	37/2,617 (1.4)	34/597 (5.7)	0.51 (0.36 - 0.70)	2.13 (1.47 - 2.99)	4.21 (2.61 - 6.78)	0.38 (0.24 - 0.59)	1.28 (0.85 -	3.38 (2.01 - 5.69)	

PSM, Propensity Score Matching; NPrNPu, neither pregnant nor puerperal; OR, Odds Ratio; 95%Cl, 95% confidence interval; SpO2, oxygen saturation in room air; SARI, temperature ≥ 38°C, cough, and onset in 10 days

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

A remarkable fact related to hospital-acquired COVID-19 is that pregnant women developed the disease less frequently (1.4%) than neither pregnant nor puerperal women (2.8%) and puerperal women (5.7%). A PSM analysis of the statistical differences between the groups, especially regarding age, skin color/ethnicity, and comorbidities, showed that pregnant women had cough more frequently than neither pregnant nor puerperal women. Sore throat and fatigue did not differ significantly between the groups. The remainder of the PSM analysis comparing pregnant and puerperal women with neither pregnant nor puerperal yielded similar results to the general analysis. When comparing puerperal to pregnant women, the only difference was a higher frequency of respiratory discomfort in the first group. Pregnant, compared to neither pregnant nor puerperal women, were less likely to have any of the study outcomes (admission to ICU, invasive and noninvasive respiratory support, and death). On the other hand, puerperal women, when contrasted with neither pregnant nor puerperal, were more likely to be admitted to the ICU and less likely to need noninvasive support. Puerperal had a higher risk of needing admission to the ICU, requiring invasive respiratory support, and dying, than pregnant women (Table 3).

Table 3. Comparison of outcomes in pregnant, puerperal, and neither pregnant nor puerperal reproductive age women before and after propensity score matching—Brazil, February 17, 2020—January 02, 2021

Outcome	Neither pregnant nor puerperal	Pregnant	Puerpera 	Group comparison			Group comparison after PSM (age + ethnicity + schooling + FUB + chronic cardiovascular disease + asthma + diabetes + immunosuppression + obesity + respiratory symptoms)		
	n (%)	n (%)	n (%)	Pregnant vs. NPrNPu OR (95% CI)	Puerperal vs. NPrNPu OR (95% CI)	Puerpera I vs. Pregnant OR (95%	Pregnant vs. NPrNPu OR (95%	Puerpera l vs. NPrNPu OR (95%	Puerpera I vs. Pregnant OR (95%

							CI)	CI)	CI)	CI)
ICU admission		80 14/2 9, 36	574/2,72	244/680	0.71 (0.65 –	1.49 (1.27 –	2.09	0.58	1.14	1.97
	(n=32,769)		1 (21.1)	(35.9)	0.78)	1.75)	(1.74 –	(0.48 –	(0.91 –	(1.62 –
(11-32	., 703	8 (27.3)	1 (21.1)	(33.3)	0.76	1.73)	2.51)	0.71)	1.43)	2.40)
Ventilato	No	n=28, 199	n=2,598	n=660						
	v	2.526		422	0.42./0.26	1 22 (1 00	2.96	0.48	1.29	2.71
ry	Yes,	3,536	209 (8.0)	133	0.42 (0.36 -	1.23 (1.00 –	(2.31 –	(0.33 -	(0.96 -	(1.91 -
support (n=31,45	invasive	(12.5)		(20.2)	0.48)		3.79)	0.68)	1.74)	3.82)
7)	Yes,	13,213	763	178	0.41 (0.37 –	0.44 (0.37 –	1.09	0.59	0.65	1.10
*1	no ninvas (46.9)		(27.0)	0.41 (0.37 -	0.53)	(0.89 –	(0.47 -	(0.51 -	(0.86 -	
	ive	(40.3)	(23.4)	(27.0)	0.44)	0.33)	1.33)	0.75)	0.83)	1.42)
		4,534/32,0	191/2 00	114/715	0.40 (0.34 -	1.15 (0.94 –	2.85	0.43	1.09	2.51
Death (n	Death (n=35, 700)		181/2,90	,	,	,	(2.22 –	(0.34 –	(0.86 –	(1.90 —
		81 (14. 1)	4 (6.2)	(15.9)	0.47)	1.41)	3.66)	0.54)	1.38)	3.31)

PSM, Propensity Score Matching; NPrNPu, neither pregnant nor puerperal; OR, Odds Ratio; 95%Cl, 95% confidence interval; FUB, Federative Unit of Brazil; ICU, Intensive Care Unit

After PSM (with the inclusion schooling, Federative Unit of Brazil, and respiratory symptoms variables), the only difference between this analysis and the general analysis was that puerperal women were no longer more likely than neither pregnant nor puerperal women to be admitted to ICU, while maintaining a worse prognosis than that of pregnant women with respect to admission to the ICU, invasive ventilatory support, and death.

Pregnant women with chronic cardiovascular or renal disease, asthma, diabetes, immunodepression, or obesity, and those in the ICU, or those who received ventilatory support were less likely to die than neither pregnant nor puerperal women with the same characteristics (Table 4). Puerperal women did not differ significantly from neither pregnant nor puerperal regarding the study variables. Puerperal women had a greater likelihood of dying than pregnant women when both had asthma, diabetes, or obesity, or when received noninvasive ventilatory support, or were admitted to the ICU. After PSM, of women with chronic cardiovascular disease or diabetes and of those admitted to ICU or who received noninvasive support, pregnant were less likely to die than neither pregnant nor puerperal women.

Table 4. Comparison of the death rates of pregnant, puerperal, and neither pregnant nor puerperal reproductive age women before and after propensity score matching according to comorbidities, ICU admission, and ventilatory support – Brazil, February 17, 2020 – January 02, 2021

Variable	Death rate			Group comparison			Group comparison after PSM (age + ethnicity + schooling + FUB + chronic cardiovascular disease + asthma + diabetes + immunosuppression + obesity + respiratory symptoms)		
	Neither pregnant nor puerperal	Pregnant	Puerperal	Pregnant vs. NPrNPu OR (95% CI)	Puerperal vs. NPrNPu OR (95% CI)	Puerperal vs. Pregnant OR (95% CI)	Pregnant vs. NPrNPu OR (95% CI)	Puerperal vs. NPrNPu OR (95% CI)	Puerperal vs. Pregnant OR (95% CI)
Chronic cardiovascular disease (n=5,349)	1,159/5,093 (22.8)	24/186 (12.9)	15/70 (21.4)	0.51 (0.32 – 0.77)	0.93 (0.51 -1.62)	1.84 (0.88 -3.75)	0.47 (0.28 – 0.79)	0.96 (0.52 - 1.75)	2.02 (0.97 -4.24)
Asthma (n=1,804)	254/1,658 (15.3)	8/119 (6.7)	6/27 (22.2)	0.41 (0.18 – 0.79)	1.61 (0.58 -3.82)	3.93 (1.16 -12.75)	0.56 (0.20 – 1.59)	2.68 (0.99 - 7.20)	4.79 (1.27 - 18.02)
Diabetes (n=4,539)	1,143/4,268 (26.8)	27/212 (12.7)	19/59 (32.2)	0.40 (0.26 – 0.59)	1.30 (0.73 -2.23)	3.24 (1.62 -6.41)	0.43 (0.26 - 0.72)	1.52 (0.85 - 2.70)	3.50 (1.70 - 7.22)
Immunode pression (n=1,213)	408/1, 159 (35.2)	6/36 (16.7)	3/18 (16.7)	0.38 (0.14 – 0.85)	0.38 (0.08 - 1.18)	1.02 (0.18 -4.62)	0.54 (0.19 – 1.48)	0.55 (0.15 - 1.98)	1.03 (0.21 -5.01)
Chronic Renal disease (n=995)	385/963 (40.0)	2/21 (9.5)	4/11 (36.4)	0.17 (0.02 – 0.59)	0.87 (0.22 -2.98)	4.96 (0.74 -47.5)	0.59 (0.12 – 2.82)	1.52 (0.41 - 5.65)	2.56 (0.37 - 17.61)
Obesity (n= 3,500)	762/3,327 (22.9)	19/125 (15.2)	15/48 (31.2)	0.61 (0.36 – 0.97)	1.54 (0.80 -2.80)	2.52 (1.14 -5.55)	0.80 (0.42 – 1.53)	2.29 (1.22 - 4.30)	2.84 (1.19 -6.78)
Invasive respiratory support (n=3,878)	2,249/3,536 (63.6)	104/209 (49.8)	77/133 (57.9)	0.57 (0.43 – 0.75)	0.79 (0.55 - 1.12)	1.39 (0.89 -2.16)	0.68 (0.38 – 1.21)	0.83 (0.46 - 1.48)	1.22 (0.75 - 1.99)
Noninvasive respiratory support (n=14,154)	1246/13,213 (9.4)	37/763 (4.8)	18/178 (10.1)	0.49 (0.35 – 0.69)	1.09 (0.64 - 1.73)	2.21 (1.20 -3.95)	0.48 (0.30 – 0.77)	0.92 (0.53 - 1.60)	1.93 (1.02 -3.63)
ICU admission (n=8,832)	2,755/8,014 (34.4)	127/574 (22.1)	90/244 (36.9)	0.54 (0.44 – 0.66)	1.12 (0.85 - 1.45)	2.06 (1.48 -2.85)	0.69 (0.48 – 0.99)	1.27 (0.88 - 1.83)	1.84 (1.28 -2.64)

PSM, Propensity Score Matching; NPrNPu, neither pregnant nor puerperal; OR, Odds Ratio; 95%Cl, 95% confidence interval; FUB, Federative Unit of Brazil; ICU, Intensive Care Unit

### **Discussion**

The results of the current analysis show that at hospital admission, both pregnant and puerperal women, in general, presented a lower rate of symptoms than neither pregnant nor puerperal women, except for cough, anosmia, and ageusia of pregnant women. On the other hand, the

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

12

pregnant and puerperal women showing fewer symptoms than nonpregnant women. Nevertheless,

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

Our study has the following strong points: 1) the use of a national database with a large sample size number and no duplicates; 2) patients who were hospitalized due to severe acute respiratory syndrome, which was confirmed by the RT-PCR laboratory test; 3) discrimination between pregnant and puerperal women for a more accurate analysis of the obstetric population; 4) the use of paired comparison analysis through propensity score matching, which allowed adjustments for the demographic data and comorbidities to evaluate symptoms and outcomes. As study limitations, a comparison with those infected with COVID-19 in the general population could not be made because only hospitalized cases with SARS and deaths are notified, and bias introduced by missing variables cannot be eliminated. In the present study, the death risk of each comorbidity was identified separately for the three groups of women: pregnant, puerperal, and neither pregnant nor puerperal. This enabled the use of ORs included in the risk calculations for the COVID-19 progression at hospital admission. Since puerperal women were at a higher risk for the most severe outcomes (need for ICU, use of invasive ventilatory support, and death), the fact that pregnancy is over must not underestimate the severity risks. Thus, in those cases in which the SARS-CoV-2 infection is acquired at the end of pregnancy, the delivery should be considered only after overcoming the disease. When it is acquired during the puerperal period, health professionals should remain alert to the severityrelated risks. It would be ideal if all women were vaccinated to minimize the risks of SARS-CoV-2 infection and if they adhered to protection measures to prevent contamination by the virus. As puerperal turned out to be a higher risk group than pregnant women among those hospitalized due to COVID-19, we need more studies comparing these groups. Furthermore, it should be considered that childbirth might influence the progression of COVID-19.

# Data availability statement

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

271 <a href="https://github.com/observatorioobstetrico/paper covid19 groups">https://github.com/observatorioobstetrico/paper covid19 groups</a>. These data were derived from

272 the following resources available in the public domain:

https://opendatasus.saude.gov.br/dataset/bd-srag-2020 obtained on January 11, 2021.

## **Acknowledgments**

- 276 This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation [INV-027961].
- 277 Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License
- 278 has already been assigned to the Author Accepted Manuscript version that might arise from this
- 279 submission.

273

274

275

280

281

### References

- 282 1. World Health Organization. WHO Director-General's opening remarks at the media briefing on
- 283 COVID-19 11 March 2020. Available from: https://www.who.int/director-
- 284 general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-
- 285 19---11-march-2020
- 286 2. WHO COVID-19 Dashboard [Internet]. Geneva: World Health Organization, 2021 [cited 2021]
- Jun 28]. Available from: https://covid19.who.int/
- 288 3. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W,et al. Clinical characteristics and intrauterine
- vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective
- 290 review of medical records. *Lancet*. 2020;395(10226):809-815.
- 4. Mullins E, Evans D, Viner RM, O'Brien P, Morris E. Coronavirus in pregnancy and delivery: rapid
- 292 review. Ultrasound Obstet Gynecol. 2020;55(5):586-592.

- 293 5. Kasraeian M, Zare M, Vafaei H, Asadi N, Faraji A, Bazrafshan K, et al. COVID-19 pneumonia and
- pregnancy; a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2020;1-8.
- 295 6. Zaigham M, Andersson O. Maternal and perinatal outcomes with COVID-19: A systematic review
- of 108 pregnancies. Acta ObstetGynecolScand. 2020;99(7):823-829.
- 7. Di Toro F, Gjoka M, Di Lorenzo G,De Santo D, De Seta F, Maso G, et al. Impact of COVID-19 on
- 298 maternal and neonatal outcomes: a systematic review and meta-analysis. Clin Microbiol Infect.
- 299 2021;27(1):36-46.
- 300 8. Elshafeey F, Magdi R, Hindi N, Elshebiny M, Farrag N, Mahdy S, et al. A systematic scoping review
- of COVID-19 during pregnancy and childbirth. Int J Gynaecol Obstet. 2020;150(1):47-52.
- 302 9. Huntley BJF, Huntley ES, Di Mascio D, Chen T, Berghella V, Chauhan SP. Rates of Maternal and
- 303 Perinatal Mortality and Vertical Transmission in Pregnancies Complicated by Severe Acute
- Respiratory Syndrome Coronavirus 2 (SARS-Co-V-2) Infection: A Systematic Review. Obstet Gynecol.
- 305 2020;136(2):303-312.
- 306 10. Sentilhes L, De Marcillac F, Jouffrieau C, Kuhn P, Thuet V, Hansmann Y, et al. Coronavirus
- 307 disease 2019 in pregnancy was associated with maternal morbidity and preterm birth. Am J Obstet
- 308 Gynecol. 2020;223(6):914.e1-914.e15.
- 309 11. Badr DA, Mattern J, Carlin A, Cordier AG, Maillart E, El Hachem L, et al. Are clinical outcomes
- 310 worse for pregnant women at ≥20 weeks' gestation infected with coronavirus disease 2019? A
- 311 multicenter case-control study with propensity score matching. Am J Obstet Gynecol.
- 312 2020; 223(5):764-768.
- 313 12. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk
- 314 factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living
- 315 systematic review and meta-analysis. BMJ. 2020;370:m3320.

- 316 13. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: Characteristics
- of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by
- Pregnancy Status United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep.
- 319 2020;69(44):1641-1647.
- 320 14. Martinez-Portilla RJ, Sotiriadis A, Chatzakis C, Torres-Torres J, Espino Y Sosa S, et al. Pregnant
- 321 women with SARS-CoV-2 infection are at higher risk of death and pneumonia: propensity score
- matched analysis of a nationwide prospective cohort (COV19Mx). Ultrasound Obstet Gynecol.
- 323 2021;57(2):224-231.
- 324 15. Knight M, Bunch K, Vousden N, Morris E, Simpson N, Gale C, et al. Characteristics and outcomes
- of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national
- population-based cohort study. BMJ. 2020;369:m2107.
- 16. Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, Seferovic MD, Aski SK, Arian SE, et al. Maternal
- death due to COVID-19. Am J Obstet Gynecol. 2020;223(1):109.e1-109.e16.
- 329 17. Vallejo V, Ilagan JG. A Postpartum Death Due to Coronavirus Disease 2019 (COVID-19) in the
- 330 United States. ObstetGynecol. 2020;136(1):52-55.
- 331 18. Lumbreras-Marquez MI, Campos-Zamora M, Lizaola-Diaz de Leon H, Farber MK. Maternal
- mortality from COVID-19 in Mexico. Int J Gynaecol Obstet. 2020;150(2):266-267.
- 19. Kayem G, Lecarpentier E, Deruelle P, Bretelle F, Azria E, Blanc J, et al. A snapshot of the Covid-19
- pandemic among pregnant women in France. J GynecolObstet Hum Reprod. 2020;49(7):101826.
- 335 20. Takemoto MLS, Menezes MO, Andreucci CB, Nakamura-Pereira M, Amorim MMR, Katz L,et al.
- 336 The tragedy of COVID-19 in Brazil: 124 maternal deaths and counting. Int J Gynaecol Obstet.
- 337 2020;151(1):154-156.

- 338 21. Menezes MO, Takemoto MLS, Nakamura-Pereira M, Katz L, Amorim MMR, Salgado HO, et al.
- 339 Risk factors for adverse outcomes among pregnant and postpartum women with acute respiratory
- distress syndrome due to COVID-19 in Brazil. Int J Gynaecol Obstet. 2020;151(3):415-423.
- 341 22. Amorim MMR, Soligo Takemoto ML, Fonseca EBD. Maternal deaths with coronavirus disease
- 342 2019: a different outcome from low- to middle-resource countries? Am J Obstet Gynecol.
- 343 2020; 223(2):298-299.
- 344 23. Takemoto M, Menezes MO, Andreucci CB, Knobel R, Sousa L, Katz L, et al. Clinical characteristics
- and risk factors for mortality in obstetric patients with severe COVID-19 in Brazil: a surveillance
- 346 database analysis. BJOG. 2020;127(13):1618-1626.
- 347 24. Brasil. Ministério da Saúde. Definição de Caso e Notificação. Available from:
- 348 https://www.gov.br/saude/pt-br/coronavirus/artigos/definicao-e-casos-suspeitos. Retrieved
- 349 04/04/2021.
- 350 25. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of
- 351 Confounding in Observational Studies. Multivariate Behav Res. 2011;46(3):399-424.
- 352 26. R Core Team. R: A language and environment for statistical computing. R Foundation for
- 353 Statistical Computing, Vienna, Austria, 2020. Version 4.0.3 [software]. 2020 Oct 10 [cited 2021 Jan
- 354 15]. Available from: https://www.r-project.org/
- 355 27. Greifer N. Weightlt: Weighting for Covariate Balance in Observational Studies. R package
- version 0.10.2 [software]. 2020 Sep 20 [cited 2021 Jan 15]. Available from: https://cran.r-
- 357 project.org/package=WeightIt
- 358 28. Collin J, Byström E, Carnahan A, Ahrne M. Public Health Agency of Sweden's Brief Report:
- 359 Pregnant and postpartum women with severe acute respiratory syndrome coronavirus 2 infection
- in intensive care in Sweden. Acta ObstetGynecol Scand. 2020;99(7):819-822.

